drugset
drugset / Trial / NCT02601001

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

NCT02601001 ↗

Phase 1 Completed 50 enrolled Cytokinetics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.

Timeline

Start
2015-11-13
Primary completion
2016-01-06
Completion
2016-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Omecamtiv Mecarbil Small molecule 25 mg Oral
Subject Omecamtiv Mecarbil Small molecule 37.5 mg Oral
Subject Omecamtiv Mecarbil Small molecule 50 mg Oral

Indications

No indication recorded.